101
|
Fernandez AI, Graham G, Győrffy B, Cavalli L, Mahajan A, Riggins RB. Abstract P3-07-09: ERRβ copy number and expression in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) is a highly aggressive form of breast cancer prevalent in African-American (AA) women defined as estrogen receptor- (ER), progesterone receptor- (PR), and human epidermal growth factor receptor 2- (HER2) negative. Because ER- and HER2-targeted therapies are ineffective in TNBC, systemic chemotherapy is the standard of care and there is a tremendous need for new effective therapies with less toxicity. Steroid hormone receptors are highly druggable targets, and orphan nuclear receptors, members of the nuclear receptor superfamily, are emerging as targets for cancer therapy. In fact, we have previously shown that treatment of TNBC cells with a small molecule agonist ligand (DY131) for estrogen related receptor beta (ERRβ), has growth inhibitory and anti-mitotic activity. We have also shown that increased mRNA expression of ERRβ, correlates with better recurrence- and distant metastasis-free survival in TNBC/basal-like breast cancer. The goal of our current work is to comprehensively characterize ERRβ copy number and mRNA status in TNBC and determine its association with patients' prognosis.
Methods: ESRRB copy number was determined in 106 primary breast tumors (TNBC n=56, nonTNBC n=50) by array-CGH, using the Agilent SurePrint G3 Human CGH platform. ESRRB mRNA data and its association with overall survival was determined in systemically untreated patients from METABRIC using Illumina gene expression array data (probe ID ILMN_1707398).
Results: Copy number alterations (CNAs). Copy number losses at the ESRRB locus (14q24.3) were observed in 10/56 (17.8%) of TNBC vs. 10/50 (20%) of nonTNBC, while copy number gains were detected in 43/56 (76.8%) of TNBC vs. 29/50 (58%) of nonTNBC (c2 *p=0.036). Interestingly, in both TNBC and non-TNBC, ESRRB loss was seen with markedly higher frequency in AA patients when compared to Caucasian (CA) patients (c2 *p=0.012 for TNBC, p=0.052 for non-TNBC). mRNA expression. Among patients not treated with systemic chemotherapy in the METABRIC dataset, low ESRRB mRNA was significantly associated with shorter overall survival in TNBC, but not ER+ or HER2+ patients (TNBC hazard ratio 0.24, 95% confidence interval 0.07-0.85, *p=0.016). Low ESRRB also correlated with reduced overall survival in TP53 mutant (but not wild type) tumors (hazard ratio 0.28, 95% confidence interval 0.1-0.82, *p=0.013).
Conclusions: ESRRB presents significantly high levels of copy number losses in TNBC when compared to non-TNBC tumors. In breast tumors from AA women, both the TNBC and non-TNBC subtypes are significantly more likely to have reduced ESRRB copy number vs. CA women. Low ESRRB mRNA expression predicts for poor overall survival in TNBC and TP53 mutant tumors. These data advocate that ERRβ expression has prognostic value in breast cancer, particularly TNBC. Future goals include immunohistochemistry staining, and analysis, of a tissue microarray consisting of 150 primary breast tumors (50 TNBC, 50 ER+, 50 HER2+); as well as ERRβ overexpression and knock-down studies in TNBC cell lines to define the role it plays in TNBC.
Citation Format: Fernandez AI, Graham G, Győrffy B, Cavalli L, Mahajan A, Riggins RB. ERRβ copy number and expression in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-07-09.
Collapse
|
102
|
Mahajan A, Arora R, Dinand V, Kalra M, Jain S, Bakhshi S, Singh M, Seth R, Verma N, Kumar A, Radhakrishnan V, Mandal P, Kapoor G, Phulkar S, Arora A, Taluja A, Chandra J. Hodgkin lymphoma in the children under 5 years of age: do they behave diiferently? PEDIATRIC HEMATOLOGY ONCOLOGY JOURNAL 2018. [DOI: 10.1016/j.phoj.2018.11.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
103
|
Noronha V, Zanwar S, Joshi A, Patil VM, Mahajan A, Janu A, Agarwal JP, Bhargava P, Kapoor A, Prabhash K. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. Clin Oncol (R Coll Radiol) 2018; 30:23-29. [PMID: 29239731 DOI: 10.1016/j.clon.2017.11.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Revised: 10/08/2017] [Accepted: 10/16/2017] [Indexed: 02/05/2023]
|
104
|
Mathew AS, Agarwal JP, Munshi A, Laskar SG, Pramesh CS, Karimundackal G, Jiwnani S, Prabhash K, Noronha V, Joshi A, Rangarajan V, Purandare NC, Jambhekar N, Tandon S, Mahajan A, Kumar R, Deodhar J. A prospective study of telephonic contact and subsequent physical follow-up of radically treated lung cancer patients. Indian J Cancer 2017; 54:241-252. [PMID: 29199699 DOI: 10.4103/0019-509x.219599] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND We tested the hypothesis that telephonic follow-up (FU) may offer a convenient and equivalent alternative to physical FU of radically treated lung cancer patients. DESIGN Prospective study carried out at a tertiary referral cancer care institute, Mumbai. MATERIALS AND METHODS Two hundred consecutive lung cancer patients treated with curative intent were followed up regularly with telephonic interviews paired with their routine physical FU visits. Patient satisfaction with the telephonic call and the physical visit, the anxiety level of the patient after meeting the physician and the economic burden of the visit to the patient were noted in a descriptive manner. Kappa statistics was used to assess concurrence between the telephonic and physical impression of disease status. RESULTS With a median FU duration of 21.5 months, the median satisfaction scores for telephonic and physical FU were 8 and 9, respectively. The prevalence and bias adjusted kappa (PABAK) score of the entire cohort of patients was 0.64 (95% confidence interval [CI] =0.58-0.70). Data analyzed up to first disease progression/relapse on FU had a PABAK score of 0.71 (95% CI = 0.64-0.77) indicating substantial agreement. Patients with disease controlled at the FU had a significant PABAK score of 0.88 (95% CI = 0.80-0.94) indicating excellent concurrence. On average, each patient spent Rs. 5117.10 on travel and Rs. 3079.06 on lodging per FU visit. CONCLUSION Telephonic FU is substantially accurate in assessing disease status until the first relapse. In a resource-constrained country like India, it is worthwhile to further explore the benefits of such an alternative strategy.
Collapse
|
105
|
Joshi AP, Chandrakanth MV, Noronha V, Patil V, Chougule A, Mahajan A, Janu AK, Chanana R, Prabhash K. Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent. Indian J Cancer 2017; 54:144-147. [PMID: 29199678 DOI: 10.4103/ijc.ijc_186_17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Ceritinib is a novel ALK inhibitor approved for advanced stage NSCLC with ALK gene rearrangement, progressed and/or intolerant to crizotinib. 13 patients were included in our study who received ceritinib. Majority of them were women and never smokers with a median age of 47 yrs. Nearly half of them had a compromised performance status and received ceritinib in third line and beyond. Ceritinib showed nearly 50% response rates. With a median follow up of 9 months for the entire cohort, median PFS and OS were not reached. However, the mean values for PFS and OS were 10.9 and 14.8 months,with an estimated 1 year PFS and OS being 56% and 78% respectively.1/3 of the patients had gastrointestinal and liver toxicities. Metabolic abnormalities were seen in 1/4 th of them. ceritinib was permanently discontinued in one patient due to pneumonitis. In conclusion, ceritinib has a favorable efficacy and side effect profile in our patient population., similar to that reported in large clinical trials. It has shown promising efficacy even in patients with compromised performance status; presence of brain metastases and heavily pre-treated disease.
Collapse
|
106
|
Noronha VM, Jandyal S, Joshi A, Patil VM, Mahajan A, Prabhash K. Expanded panel test detecting mesenchymal-epithelial transition amplification leading to effective treatment in adenocarcinoma lung. Indian J Cancer 2017; 54:325-326. [PMID: 29199715 DOI: 10.4103/0019-509x.219596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
107
|
Talreja V, Patil V, Joshi A, Noronha V, Chandrasekharan A, Dhumal S, Pande N, Turkar S, Shrirangwar S, Mahajan A, Juvrekar S, Bhattacharjee A, Prabhash K. Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx665.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
108
|
Prabhash K, Patil V, Joshi A, Noronha V, Pande N, Chandrasekaran A, Mahajan A, Janu A. PUB059 Gefitinib Versus Pemetrexed-Platinum Therapy in EGFR Activating Mutated Lung Cancer: Impact on Brain Metastasis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
109
|
Kapoor A, Noronha V, Joshi A, Patil V, Kaushal R, Mahajan A, Janu A, Prabhash K. P1.01-021 FISH and IHC Discordance in ALK Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
110
|
Talreja V, Patil V, Joshi A, Noronha V, Mv C, Kaushal R, Mahajan A, Janu A, Prabhash K. P3.03-015 ROS-1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
111
|
Ludmir E, Paulino A, Grosshans D, McAleer M, McGovern S, Huh W, Okcu M, Harrell L, Mahajan A. Regional Nodal Failure in Head and Neck Alveolar Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
112
|
Kapoor A, Zanwar S, Joshi A, Noronha V, Patil V, Chougule A, Mahajan A, Bhargava P, Prabhash K. Real world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx379.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
113
|
Rangrej S, Mahajan A, Kakar S. Branching pattern of superior mesenteric artery and its clinical importance – Anatomical study. J ANAT SOC INDIA 2017. [DOI: 10.1016/j.jasi.2017.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
114
|
Costa R, Seth A, Chandra P, Bhal V, Nanjappa M, Rath P, Kalaricka M, Wander G, Mahajan A, Kumaran A, Koshy A, Goel P, Kumar V, Kaul U, Trehan V. 1968Quantitative angiographic analysis in patients with de novo native coronary artery lesions treated with novel poly-l-lactide based sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 Trial. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
115
|
Tobase P, Mahajan A, Francis D, Leavitt AD, Giermasz A. A gap in comprehensive care: Sexual health in men with haemophilia. Haemophilia 2017; 23:e389-e391. [DOI: 10.1111/hae.13276] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2017] [Indexed: 12/31/2022]
|
116
|
Feldkoren B, Hutchinson R, Rapoport Y, Mahajan A, Margulis V. Integrin signaling potentiates transforming growth factor-beta 1 (TGF-β1) dependent down-regulation of E-Cadherin expression – Important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma. Exp Cell Res 2017; 355:57-66. [DOI: 10.1016/j.yexcr.2017.03.051] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 03/21/2017] [Accepted: 03/23/2017] [Indexed: 11/26/2022]
|
117
|
Tonse R, Sood S, Gupta T, Moiyadi A, Upreti R, Shastri J, Shetty P, Mahajan A, Bano N, Jalali R. P09.61 Detailed analysis and correlation of survival with subventricular zone dosimetry in patients diagnosed with glioblastoma treated with focal conformal radiotherapy: Results of a prospective trial. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.316] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
118
|
Gupta N, Yadav V, Deshpande A, Patel M, Mahajan A, Kumar R, Sharma M, Patel M. Solid pseudo-papillary tumor of the pancreas: a single centre experience. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30354-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
119
|
Prabhash K, Noronha V, Chandrakanth MV, Joshi AP, Patil V, Chougule A, Mahajan A, Janu AK, Chanana R. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience. Indian J Cancer 2017; 54:436-438. [PMID: 29469073 DOI: 10.4103/ijc.ijc_269_17] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
120
|
Noronha V, Chandrakanth MV, Joshi A, Patil V, Mahajan A, Prabhash K. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status. Indian J Cancer 2017; 54:55-56. [PMID: 29199664 DOI: 10.4103/ijc.ijc_10_17] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
121
|
Mahajan A, Vaish R, Sable N, Arya S, Kane S, D'Cruz A. 391P Incremental value of preoperative CT in the surgical management of papillary thyroid cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw587.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
122
|
Vaish R, Mahajan A, Shah S, Sharma S, Chaukar D, Thiagarajan S, D'Cruz A. 166P Extent of neck dissection in locally advanced thyroid cancers. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw580.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
123
|
Mahajan A, Vaish R, Sable N, Arya S, Kane S, D'Cruz A. 391P Incremental value of preoperative CT in the surgical management of papillary thyroid cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00549-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
124
|
Basu S, Mahajan A. Discordant and aggressive tumor biology of solitary scalp metastasis amidst widespread skeletal metastases in differentiated thyroid carcinoma: Functional radionuclide and MR imaging features and clinical correlates. Indian J Cancer 2016; 51:613-4. [PMID: 26842213 DOI: 10.4103/0019-509x.175309] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
125
|
Mohan A, Venkatramani R, Okcu M, Nuchtern J, Vasudevan S, Mahajan A, Rainusso N, Allen-Rhoades W, Chintagumpala M, Paulino A. The Role of Local Therapy to Distant Metastatic Sites in Stage IV Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|